← Back to Patent Explorer
US4755518A Expired / Lapsed US ⏱️ 0.0 years remaining

Imidazolyl or tetrazolyl substituted benzoic acid derivatives and pharmaceutical compositions thereof

Assignee: Warner Lambert Co LLC
•
Filing: 1986-11-10
•
Granted: 1988-07-05
•
Expires: 2006-11-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel benzoic acid or benzoic acid ester derivatives, pharmaceutical compositions and methods of use thereof are the present invention. Utility is for the treatment of arthritis, asthma, Raynaud's disease, inflammatory bowel disorders, trigeminal or herpetic neuralgia, inflammatory eye disorders, psoriasis, dental pain, and headaches, particularly vascular headaches, such as migraine, cluster, mixed vascular syndromes, as well as nonvascular, tension headaches.

Inventors

  • 👤 Michael F. Rafferty
  • 👤 Graham Johnson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 22:00
CPC Classifications
C; C07; C07D; C07D257/00; C07D257/02; C07D257/04

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 124 words
A compound of the formula: ##STR9## wherein: (a) R 1 is tetrazolyl or COOR' wherein R' is H or lower alkyl of one to four carbons, inclusive; (b) B is ##STR10## (c) X and Y are independently H or lower alkyl of one to four carbons, inclusive; (d) R 2 is alkylene, alkenylene, alkynylene branched or linear chains of 1 to 11 carbons, inclusive; (e) Q is CH 3 , COOH, Br, NH 2 , H, imidazolyl, cyclohexyl, ##STR11## with the proviso that when B is (B 1 ) and Q is H, R 2 is not methylene and further with the proviso that when R 1 is COOR' then Q consists of imidazolyl; or nontoxic, pharmaceutically acceptable acid addition or base salt thereof.
Claim 2
Dependent Claim 124 words
A compound of the formula: ##STR9## wherein: (a) R 1 is tetrazolyl or COOR' wherein R' is H or lower alkyl of one to four carbons, inclusive; (b) B is ##STR10## (c) X and Y are independently H or lower alkyl of one to four carbons, inclusive; (d) R 2 is alkylene, alkenylene, alkynylene branched or linear chains of 1 to 11 carbons, inclusive; (e) Q is CH 3 , COOH, Br, NH 2 , H, imidazolyl, cyclohexyl, ##STR11## with the proviso that when B is (B 1 ) and Q is H, R 2 is not methylene and further with the proviso that when R 1 is COOR' then Q consists of imidazolyl; or nontoxic, pharmaceutically acceptable acid addition or base salt thereof.
Claim 3
Dependent Claim 10 words
A compound of claim 1 wherein R 1 is tetrazolyl.
Claim 4
Dependent Claim 8 words
A compound of claim 2 and being N-[[4-(1H-tetrazol-5-yl)phenyl]methyl]nonanamide.
Claim 5
Dependent Claim 115 words
A pharmaceutical composition comprising an effective amount of a compound of the formula: ##STR12## Wherein: (a) R 1 is tetrazolyl or COOR' wherein R' is H or lower alkyl of one to four carbons, inclusive; (b) B is ##STR13## (c) X and Y are independently H or lower alkyl of one to four carbons, inclusive; (d) R 2 is alkylene, alkenylene, alkynylene branched or linear chains of 1 to 11 carbons, inclusive; (e) Q is CH 3 , COOH, Br, NH 2 , H, imidazolyl, cyclohexyl, ##STR14## with the proviso that when R 1 is COOR' then Q is imidazolyl or nontoxic, pharmaceutically acceptable acid addition or base salt thereof; and a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim 115 words
A pharmaceutical composition comprising an effective amount of a compound of the formula: ##STR12## Wherein: (a) R 1 is tetrazolyl or COOR' wherein R' is H or lower alkyl of one to four carbons, inclusive; (b) B is ##STR13## (c) X and Y are independently H or lower alkyl of one to four carbons, inclusive; (d) R 2 is alkylene, alkenylene, alkynylene branched or linear chains of 1 to 11 carbons, inclusive; (e) Q is CH 3 , COOH, Br, NH 2 , H, imidazolyl, cyclohexyl, ##STR14## with the proviso that when R 1 is COOR' then Q is imidazolyl or nontoxic, pharmaceutically acceptable acid addition or base salt thereof; and a pharmaceutically acceptable carrier.

References Cited (Backward Citations)

US3514383A Cited
US3953499A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-07-05 1992-01-04 1992-07-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-07-05 1996-01-04 1996-07-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-07-05 2000-01-04 2000-07-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag